A Novel Ovarian Reserve Monitoring Algorithm for Patients at Risk of Ovarian Injury From Gonadotoxic Therapy

NCT ID: NCT05048654

Last Updated: 2025-09-18

Basic Information

• Recruitment Status: WITHDRAWN
• Study Classification: OBSERVATIONAL
• Study Start Date: 2025-12-15
• Study Completion Date: 2029-06-30

Brief Summary

This is an observational cohort study to examine the use of a novel proposed ovarian reserve monitoring algorithm to (1) identify patients who are at risk of DOR and POI from gonadotoxic therapy, (2) minimize time from treatment to utilization of assisted reproductive technologies, and (3) improves prognosis for successful ART based on AFC for patients who pursue fertility or fertility preservation.

Detailed Description

Study Design: This is an observational cohort study to examine the use of a novel proposed ovarian reserve monitoring algorithm to (1) identify patients who are at risk of DOR and POI from gonadotoxic therapy, (2) minimize time from treatment to utilization of assisted reproductive technologies, and (3) improves prognosis for successful ART based on AFC for patients who pursue fertility or fertility preservation.

Group B: Prospectively, survivors will be evaluated by a member of the FPRLE team in the outpatient clinic at 12 months post-therapy completion and every 6 months to 36 months as part of clinical care. AMH and FSH will be drawn at each time point.

Group A: Retrospectively, we will abstract AMH and FSH from survivors seen at CHCO and UCH from October 1st, 2016 to September 31st, 2019 and assess time points.

Approach Aim 1: The Investigator will assess AMH and FSH in both groups and evaluate whether the monitoring algorithm allows for early identification of DOR prior to the occurrence of POI. The investigator will calculate time from end of treatment to diagnosis of DOR and POI to evaluate if the monitoring algorithm detects these conditions earlier than historical controls.

Statistical analysis: The investigator will provide descriptive statistics and time to event analysis by group.

Aim 2: The Investigator will assess time from end of treatment to utilization of ART as defined by ovulation induction with or without insemination, in vitro fertilization, and/or third-party reproduction.

Statistical analysis: The Investigator will provide descriptive statistics and time to event analysis by group (A and B).

Aim 3: The Investigator will assess if early identification of DOR improves prognosis for successful ART for Group B as compared to Group A. The Investigator define success as an AFC greater than or equal to 6 at time of evaluation by REI.

Statistical analysis: The Investigator will provide descriptive statistics for the prevalence of AFC greater than 6 by group (A and B).

Aim 4: The Investigator will characterize barriers to utilization of ART by surveying participants who were referred to REI. The Investigator will assess the following: (1) if participants declined or accepted referral, (2) if they accepted, were they successful, and (3) if they declined, reasons for declining.

Conditions

Ovarian Diseases; Fertility Issues; Gonadal Disorders

Study Design

• Observational Model Type: COHORT
• Study Time Perspective: OTHER

Study Groups

Group A: Retrospective

Retrospectively, there will be an abstract of AMH and FSH from survivors seen at CHCO and UCH from October 1st, 2016 to September 31st, 2019 and assess time points.

No interventions assigned to this group

Group B: Prospective

Prospectively, survivors will be evaluated by a member of the FPRLE team in the outpatient clinic at 12 months post-therapy completion and every 6 months to 36 months as part of clinical care. Per standard of care AMH and FSH will be drawn at each time point.

No interventions assigned to this group

Eligibility Criteria

Inclusion Criteria

• · Female patients ages 8 - 39 years of age

• Seen in CHCO or AMC outpatient clinics for any of the following reasons:

• At risk for fertility problems (Z91.89)
• Encounter for fertility preservation counseling (Z31.62)
• Primary ovarian insufficiency
• Premature ovarian failure/premature menopause
• Diminished ovarian reserve
• At least 12 months post-completion of chemotherapy and/or radiation
• History of a fertility-threatening diagnosis receiving chemotherapy; radiation; or surgery to the reproductive organs for malignancy, including but not limited to:

• Any type of cancer/malignancy
• Rheumatoid arthritis
• Systemic lupus erythematosus
• Aplastic anemia
• Fanconi anemia
• Diamond-Blackfan syndrome
• Hurler syndrome
• Other autoimmune conditions

Exclusion Criteria

• Disorders of sexual development (i.e., gonadal dysgenesis, Turner syndrome/mosaicism, etc.)
• History of bilateral oophorectomy
• Transgender patients not receiving chemotherapy; radiation; or surgery to the reproductive organs for malignancy
• Inability to consent/assent

• Minimum Eligible Age: 8 Years
• Maximum Eligible Age: 39 Years
• Eligible Sex: FEMALE
• Accepts Healthy Volunteers: No

Sponsors

University of Colorado, Denver

OTHER

Sponsor Role: lead

Responsible Party

Responsibility Role: SPONSOR

Principal Investigators

Leslie Appiah, MD

Role: PRINCIPAL_INVESTIGATOR

University of Colorado, Denver

Other Identifiers

21-3085

Identifier Type: -

Identifier Source: org_study_id